ACA
KRYS icon

Apis Capital Advisors’s Krystal Biotech KRYS Stock Holding History

Apis Capital Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-24,000
Closed -$2.78M – 31
2023
Q3 		$2.78M Sell
24,000
-2,800
-10% -$342K 3.61% 9
2023
Q2 		$3.15M Buy
+26,800
New +$2.74M 3.18% 11

Other funds holding KRYS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Apis Capital Advisors's KRYS Position: Q4 2023 in Review

Apis Capital Advisors sold out of Krystal Biotech (KRYS) in Q4 2023, closing a stake of 24,000 shares — an estimated $2.78M sold.

Apis Capital Advisors first reported a position in KRYS in Q2 2023 and held it in 2 quarters. The position peaked at $3.15M in Q2 2023. 194 funds tracked by Wall St. Rank hold KRYS as of Q4 2023.

  • Apis Capital Advisors reported no remaining Krystal Biotech position as of Q4 2023 after selling out during the quarter.
  • Apis Capital Advisors sold 24,000 Krystal Biotech shares in Q4 2023, an estimated $2.78M.
  • Apis Capital Advisors first reported a position in Krystal Biotech in Q2 2023 and held it in 2 quarters.
  • Apis Capital Advisors's Krystal Biotech position peaked at $3.15M in Q2 2023.
  • 194 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2023.

Based on Apis Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.